FindTrial
Sign In

Project on the promotion of cardiovascular risk evaluation in clinical practice and the assessment of cardiovascular risk evolution after the introduction of a preventive multifactorial strategy aimed at decresing the global risk level (SCORE algorithm), in subjects affected from metabolic syndrome and with a risk level lt; or = 5%

Project on the promotion of cardiovascular risk evaluation in clinical practice and the assessment of cardiovascular risk evolution after the introduction of a preventive multifactorial strategy aimed at decresing the global risk level (SCORE algorithm), in subjects affected from metabolic syndrome and with a risk level lt; or = 5%

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-000829-30-IT
Enrollment
Unknown
Registered
2005-07-06
Start date
2004-07-06
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methabolic syndrome (preventive multifactorial strategy aimed at decresing the global risk level) in patients with a risk level lt

Interventions

Trade Name: TAREG 160*28 CPS 160 MG Product Name: NA Product Code: NA Pharmaceutical Form: INN or Proposed INN: valsartan Concentration unit: mg milligram(s) Concentration type: equal Concentration n

Sponsors

NOVARTIS FARMA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026